DealsMay 18, 2026, 06:47 AM
Context Therapeutics buys out CT-202 milestones & royalties for $6.5M
AI Summary
Context Therapeutics announced an amendment to its exclusive license agreement with BioAtla, Inc. for CT-202, its Nectin-4 x CD3 T cell engager. The amendment eliminates all future milestone and royalty obligations for CT-202 in exchange for a $4.5 million upfront payment and a final $2.0 million payment due by August 1, 2026. This transaction provides Context with full economic rights to CT-202, a key program in its pipeline, with the Phase 1 trial expected to begin in the third quarter of 2026.
Key Highlights
- Context Therapeutics amended its exclusive license agreement with BioAtla for CT-202.
- The amendment removes all future milestone and royalty obligations for CT-202.
- Context will make a $4.5 million upfront payment.
- A second and final payment of $2.0 million is due by August 1, 2026.
- Total payments for the buyout amount to $6.5 million.
- Context gains full economic rights to CT-202.
- Phase 1 trial for CT-202 is expected to initiate in Q3 2026.
Price Impact
More from CNTX